Concepedia

Author

Nichola Webster

University of Leeds

Also Known As

Lelia Duley, N. Webster, Nichola Webster

19

Publications

817

Citations

8

H-Index

18

Concepts

All Affiliations

University of LeedsKing's College LondonCancer Research UK Clinical Trials UnitThe Christie NHS Foundation TrustSt James's University Hospital
NW

About

Nichola Webster is an author at University of Leeds specializing in oncology, health sciences, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

125

2

Medicine

2

2

125

3

Immunology

2

2

125

4

Pathology

1

1

33

5

Cancer Genetics

1

1

33

Nichola Webster

×

7

Publications

784

Citations

7

H-Index

YearCitations

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart Lacy, Sharon Barrans, Philip Beer,

Blood

2020

481

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Talha Munir, David A. Cairns, Adrian Bloor,

New England Journal of Medicine

2023

138

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor,

The Lancet Oncology

2023

92

Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network

Simon Crouch, Daniel Painter, Sharon Barrans,

Blood Advances

2022

33

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, Rebecca H. Boucher, Nichola Webster,

Blood

2020

17

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Talha Munir, Louise-Rae Cherrill, Nichola Webster,

Blood

2022

12

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David A. Cairns, Adrian Bloor,

Blood

2023

11

Page 1